{"entity":{"id":"nct01954992","kind":"trial","name":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Glufosfamide in pancreatic ductal adenocarcinoma, run by Eleison Pharmaceuticals LLC., now recruiting.","summary":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT01954992 by Eleison Pharmaceuticals LLC., with 480 participants planned, started 2014-04 and due to reach its primary completion in 2026-06. Interventions recorded: Glufosfamide and Fluorouracil.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01954992","url":"https://clinicaltrials.gov/study/NCT01954992"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01954992","phase":"3","setting":"A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine","sponsor":"Eleison Pharmaceuticals LLC.","enrolled":480,"outcomes":[]},"route":"/trials/nct01954992/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}